ATE360438T1 - Verwendung von inaktives cln2 proenzym zur behandlung von lincl - Google Patents
Verwendung von inaktives cln2 proenzym zur behandlung von linclInfo
- Publication number
- ATE360438T1 ATE360438T1 AT01937337T AT01937337T ATE360438T1 AT E360438 T1 ATE360438 T1 AT E360438T1 AT 01937337 T AT01937337 T AT 01937337T AT 01937337 T AT01937337 T AT 01937337T AT E360438 T1 ATE360438 T1 AT E360438T1
- Authority
- AT
- Austria
- Prior art keywords
- cln2
- lincl
- proenzyme
- inactive
- treat
- Prior art date
Links
- 102000010911 Enzyme Precursors Human genes 0.000 title 1
- 108010062466 Enzyme Precursors Proteins 0.000 title 1
- 208000025014 late infantile neuronal ceroid lipofuscinosis Diseases 0.000 title 1
- 108010039203 Tripeptidyl-Peptidase 1 Proteins 0.000 abstract 3
- 230000007812 deficiency Effects 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
- C12Y304/14009—Tripeptidyl-peptidase I (3.4.14.9)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Compounds Of Unknown Constitution (AREA)
- Saccharide Compounds (AREA)
- Optical Integrated Circuits (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20340700P | 2000-05-11 | 2000-05-11 | |
| US09/852,918 US20020006400A1 (en) | 2000-05-11 | 2001-05-10 | Recombinant human CLN2 protein and methods of its production and use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE360438T1 true ATE360438T1 (de) | 2007-05-15 |
Family
ID=26898578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01937337T ATE360438T1 (de) | 2000-05-11 | 2001-05-11 | Verwendung von inaktives cln2 proenzym zur behandlung von lincl |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US20020006400A1 (de) |
| EP (1) | EP1292326B1 (de) |
| JP (1) | JP4843774B2 (de) |
| AT (1) | ATE360438T1 (de) |
| AU (1) | AU2001263085A1 (de) |
| BR (1) | BR0110746A (de) |
| CA (1) | CA2408380C (de) |
| DE (1) | DE60128084T2 (de) |
| MX (1) | MXPA02011162A (de) |
| WO (1) | WO2001085200A2 (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7442372B2 (en) | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| US9387236B2 (en) * | 2011-06-10 | 2016-07-12 | Prothera Inc. | Pharmaceutical compositions containing protease and methods for the treatment of lysosomal storage diseases |
| ES2432653B1 (es) * | 2012-05-23 | 2015-09-17 | Centro De Investigacion Biomedica En Red De Enfermedades Raras | Un procedimiento y kit para el diagnostico diferencial de una enfermedad que cursa con afectación muscular. |
| TWI752907B (zh) | 2015-05-08 | 2022-01-21 | 美商拜奧馬林製藥公司 | 用於治療cln2疾病之tpp1調配物及方法 |
| PT4021575T (pt) | 2019-08-29 | 2024-07-30 | Biomarin Pharm Inc | Métodos para o tratamento da doença cln2 em sujeitos pediátricos |
| WO2025221877A1 (en) | 2024-04-17 | 2025-10-23 | Five Prime Sciences Incorporated | Tripeptidyl peptidase 1-related compositions and methods for the treatment and diagnosis of amyotrophic lateral sclerosis |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6302685B1 (en) * | 1997-09-16 | 2001-10-16 | University Of Medicine And Dentistry Of New Jersey | Human lysosomal protein and methods of its use |
-
2001
- 2001-05-10 US US09/852,918 patent/US20020006400A1/en not_active Abandoned
- 2001-05-11 BR BR0110746-1A patent/BR0110746A/pt not_active Application Discontinuation
- 2001-05-11 AU AU2001263085A patent/AU2001263085A1/en not_active Abandoned
- 2001-05-11 MX MXPA02011162A patent/MXPA02011162A/es active IP Right Grant
- 2001-05-11 DE DE60128084T patent/DE60128084T2/de not_active Expired - Fee Related
- 2001-05-11 JP JP2001581853A patent/JP4843774B2/ja not_active Expired - Lifetime
- 2001-05-11 AT AT01937337T patent/ATE360438T1/de not_active IP Right Cessation
- 2001-05-11 WO PCT/US2001/015386 patent/WO2001085200A2/en not_active Ceased
- 2001-05-11 EP EP01937337A patent/EP1292326B1/de not_active Expired - Lifetime
- 2001-05-11 CA CA2408380A patent/CA2408380C/en not_active Expired - Lifetime
-
2006
- 2006-08-22 US US11/507,945 patent/US7811559B2/en not_active Expired - Lifetime
-
2010
- 2010-09-13 US US12/881,066 patent/US8029781B2/en not_active Expired - Fee Related
-
2011
- 2011-08-29 US US13/220,572 patent/US8277800B2/en not_active Expired - Fee Related
-
2012
- 2012-08-29 US US13/598,556 patent/US20130273018A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1292326B1 (de) | 2007-04-25 |
| US20130273018A1 (en) | 2013-10-17 |
| CA2408380C (en) | 2012-04-17 |
| BR0110746A (pt) | 2003-07-22 |
| WO2001085200A2 (en) | 2001-11-15 |
| CA2408380A1 (en) | 2001-11-15 |
| US7811559B2 (en) | 2010-10-12 |
| US8277800B2 (en) | 2012-10-02 |
| JP2004519415A (ja) | 2004-07-02 |
| US20110014172A1 (en) | 2011-01-20 |
| MXPA02011162A (es) | 2003-07-28 |
| JP4843774B2 (ja) | 2011-12-21 |
| DE60128084T2 (de) | 2008-01-03 |
| US20090022701A1 (en) | 2009-01-22 |
| US8029781B2 (en) | 2011-10-04 |
| US20020006400A1 (en) | 2002-01-17 |
| EP1292326A2 (de) | 2003-03-19 |
| US20120014935A1 (en) | 2012-01-19 |
| WO2001085200A3 (en) | 2002-04-11 |
| AU2001263085A1 (en) | 2001-11-20 |
| DE60128084D1 (de) | 2007-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE241358T1 (de) | Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen | |
| ATE279181T1 (de) | Verwendung von 5ht-6 antagonisten zur behandlung adhd | |
| DE60312309D1 (de) | Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten | |
| EA200001258A1 (ru) | Пирролзамещенные 2-индолиноны (варианты), фармацевтическая композиция (варианты), способ модулирования каталитической активности протеинкиназы, способ лечения или профилактики нарушения в организме, связанного с протеинкиназой | |
| ATE324908T1 (de) | Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems | |
| DE60142590D1 (de) | Verwendung von Botulinum Toxin zur Behandlung von post-operative Schmerzen | |
| ATE422357T1 (de) | Verwendung von allopurinol zur behandlung von bluthochdruck | |
| ID30237A (id) | KOMBINASI PENGHAMBAT-PENGHAMBAT FBPase DAN PEMEKA-PEMEKA INSULIN UNTUK PENGOBATAN DIABETES | |
| DE60310400D1 (de) | Botulinustoxine zur behandlung von priapismus | |
| DE60143990D1 (de) | Neue therapeutische verwendung von smr-1 peptide | |
| ATE356995T1 (de) | Verfahren zur identifizierung von mitteln zur behandlung von diabetes | |
| ATE541565T1 (de) | Topische verwendung von muskarinischen und opioiden mitteln zur behandlung von tinnitus | |
| ATE287722T1 (de) | Mittel zur behandlung maligner erkrankungen unter verwendung des proteins yb-1 | |
| ATE360438T1 (de) | Verwendung von inaktives cln2 proenzym zur behandlung von lincl | |
| DE69912743D1 (de) | Behandlung von follikulären lymphomen unter verwendung von inhibitoren des lymphotoxin (lt)-aktivierungsweges | |
| ATE298246T1 (de) | Aktiviertes protein c zur behandlung von pankreatitis | |
| ATE359808T1 (de) | Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma | |
| ATE402694T1 (de) | Verwendung von 1-phenyl-3-dimethylamino-propan- verbindungen zur therapie der harninkontinenz | |
| EP1056458A4 (de) | Methoden zur behandlung von schmerzen, einscliesslich chronischen und frauenspezifischen schmerzen | |
| ATE361071T1 (de) | Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie | |
| ATE486612T1 (de) | Verfahren zur behandlung von diabetes typ 2 | |
| ATE278401T1 (de) | Verwendung von riluzol zur behandlung von akustischen traumazuständen | |
| ATE262362T1 (de) | Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung | |
| ATE320255T1 (de) | Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen | |
| ATE291434T1 (de) | Verwendung von angiotensin zur behandlung von krebsmetastasierung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |